Cluster Headache Market by Drug class (Ergot derivatives, Calcium channel blockers, Triptans and Others), Distribution channel (Hospital pharmacies, Drug stores and retail pharmacies and Others), Type (Episodic and Chronic) and Geography (North America, Europe, Asia Pacific and RoW) – Forecast up to 2027
The most common types of primary headaches are cluster headaches which are known as trigeminal autonomic cephalgia. These cluster headaches can come every other day, one to eight times a day like other trigeminal autonomic cephalgia's. Approximately, they commonly occur at same time of the day, most often at night. Many patients are periodic, with daily attacks for weeks to months, followed by remission for months to years. As cluster headaches are rare, they can be significantly exhausting, leading to a highly reduction in quality of life. The prevalence and incidence of cluster headaches are rising, which is augmenting the demand for effective treatments which is a key driving factor. Moreover, currently, there are no FDA-approved medications especially for the cluster headaches treatment. This implies that there is a major unmet requirement for effective treatments for this condition, which is augmenting the research and development efforts in this area. On the other hand, the factors limiting the cluster headache market growth are adverse effects of cluster headache drugs. The Cluster Headache Market is anticipated to grow at a rate of 3.9% CAGR by 2027.
Cluster Headache Market by Drug class
Ergot derivatives
Calcium channel blockers
Triptans
Others
Cluster Headache Market by Distribution channel
Hospital pharmacies
Drug stores and retail pharmacies
Others
Cluster Headache Market by Type
Episodic
Chronic
Cluster Headache Market by Geography
North America
Europe
Asia Pacific
Rest of the World
The cluster headache market by drug class is divided into Ergot derivatives, Calcium channel blockers, Triptans and Others. The triptans segment holds the maximum share in the market growth. The maximum share of the segment is owing to the first line treatment for cluster headache. Triptans are a class, or group, of medicines which can stop migraine episodes. These drugs work to decrease symptoms by building enlarged blood arteries in the brain brought on by migraine attacks. Also, they are present in various dose formulations.
On the basis of distribution channel, the cluster headache market is categorized into Hospital pharmacies, Drug stores and retail pharmacies and Others. The drug stores and retail pharmacies segment held the maximum share in the market growth. This is due to the increase in consumer preference for retail pharmacies, which provide advice on drugs and their use throughout treatment periods and they also provide affordable prices.
As per the type the cluster headache market is bifurcated into Episodic and Chronic. The episodic segment accounted for the major share in the cluster headache market. The major share is owing to the surge in number of people suffering from episodic attack and increase in regulatory approval of drugs indicated for episodic cluster headache.
The regional market is divided into North America, Europe, Asia Pacific and rest of the world. North America region has occupied the major share in the cluster headache market growth due to the factors such as surge in prevalence of cluster headache cases, incidence of advanced healthcare infrastructure and rise in number of key players providing new therapeutics.
Several organizations coupled with governments across the world are counseling people about the headache disorders. E-commerce (electronic commerce) has become a significant tool for small and large businesses globally, owing to increase in preference of consumers for online shopping over conventional purchasing methods. Several animations through health apps to educate people about headache disorders and usage of medications have lead towards the growth of global cluster headache market.
Key players operating in the cluster headache market include Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., FRESENIUS SE & Co. KGaA, GlaxoSmithKline plc, Pfizer Inc., Arrotex Australia Group, Grunenthal, and Novartis AG.
As a result, the there is a major unmet requirement for effective treatments for cluster headaches. Henceforth, there is a rising focus on the development of new treatments, such as new pharmacological agents and neuromodulation devices which is projected to augment innovation in the market.
Complete information on factors is provided which will propel cluster headache market growth in the forecast period.
This report gives the exact estimation of the market size and its contribution to the parent market along with the precise estimation on upcoming trends and shifts in consumer behavior.
This research provides growth analysis of the cluster headache market among regions such as North America, Europe, Asia Pacific and rest of the world.
This report further provides comprehensive details of factors which will challenge the growth of cluster headache market players.
Cluster Headache Market by Drug class
Ergot derivatives
Calcium channel blockers
Triptans
Others
Cluster Headache Market by Distribution channel
Hospital pharmacies
Drug stores and retail pharmacies
Others
Cluster Headache Market by Type
Episodic
Chronic
Cluster Headache Market by Geography
North America
Europe
Asia Pacific
Rest of the World
The cluster headache market by drug class is divided into Ergot derivatives, Calcium channel blockers, Triptans and Others. The triptans segment holds the maximum share in the market growth. The maximum share of the segment is owing to the first line treatment for cluster headache. Triptans are a class, or group, of medicines which can stop migraine episodes. These drugs work to decrease symptoms by building enlarged blood arteries in the brain brought on by migraine attacks. Also, they are present in various dose formulations.
On the basis of distribution channel, the cluster headache market is categorized into Hospital pharmacies, Drug stores and retail pharmacies and Others. The drug stores and retail pharmacies segment held the maximum share in the market growth. This is due to the increase in consumer preference for retail pharmacies, which provide advice on drugs and their use throughout treatment periods and they also provide affordable prices.
As per the type the cluster headache market is bifurcated into Episodic and Chronic. The episodic segment accounted for the major share in the cluster headache market. The major share is owing to the surge in number of people suffering from episodic attack and increase in regulatory approval of drugs indicated for episodic cluster headache.
The regional market is divided into North America, Europe, Asia Pacific and rest of the world. North America region has occupied the major share in the cluster headache market growth due to the factors such as surge in prevalence of cluster headache cases, incidence of advanced healthcare infrastructure and rise in number of key players providing new therapeutics.
Several organizations coupled with governments across the world are counseling people about the headache disorders. E-commerce (electronic commerce) has become a significant tool for small and large businesses globally, owing to increase in preference of consumers for online shopping over conventional purchasing methods. Several animations through health apps to educate people about headache disorders and usage of medications have lead towards the growth of global cluster headache market.
Key players operating in the cluster headache market include Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., FRESENIUS SE & Co. KGaA, GlaxoSmithKline plc, Pfizer Inc., Arrotex Australia Group, Grunenthal, and Novartis AG.
As a result, the there is a major unmet requirement for effective treatments for cluster headaches. Henceforth, there is a rising focus on the development of new treatments, such as new pharmacological agents and neuromodulation devices which is projected to augment innovation in the market.
Complete information on factors is provided which will propel cluster headache market growth in the forecast period.
This report gives the exact estimation of the market size and its contribution to the parent market along with the precise estimation on upcoming trends and shifts in consumer behavior.
This research provides growth analysis of the cluster headache market among regions such as North America, Europe, Asia Pacific and rest of the world.
This report further provides comprehensive details of factors which will challenge the growth of cluster headache market players.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
3. INDUSTRY OVERVIEW
4. INDUSTRY TRENDS
5. MARKET SNAPSHOT
6. MARKET DEFINITION
7. MARKET OUTLOOK
a. Porter Five Forces
8. RELATED MARKETS
9. MARKET CHARACTERISTICS
10. MARKET OVERVIEW
11. MARKET SEGMENTATION
12. MARKET DYNAMICS
a. Drivers
b. Restraints
c. Opportunities
13. DRO - IMPACT ANALYSIS
14. DRUG CLASS: MARKET SIZE & ANALYSIS
15. OVERVIEW
16. ERGOT DERIVATIVES
17. CALCIUM CHANNEL BLOCKERS
18. TRIPTANS
19. OTHERS
20. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
21. OVERVIEW
22. HOSPITAL PHARMACIES
23. DRUG STORES AND RETAIL PHARMACIES
24. OTHERS
25. TYPE: MARKET SIZE & ANALYSIS
26. OVERVIEW
27. EPISODIC
28. CHRONIC
29. GEOGRAPHY: MARKET SIZE & ANALYSIS
30. OVERVIEW
31. NORTH AMERICA
32. EUROPE
33. ASIA PACIFIC
34. REST OF THE WORLD
35. COMPETITIVE LANDSCAPE
36. COMPETITOR COMPARISON ANALYSIS
37. MARKET DEVELOPMENTS
a. Mergers and Acquisitions, Legal, Awards, Partnerships
b. Product Launches and execution
38. VENDOR PROFILES
39. DR. REDDY’S LABORATORIES LTD.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
40. ELI LILLY AND COMPANY
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
41. SUN PHARMACEUTICAL INDUSTRIES LTD.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
42. TEVA PHARMACEUTICAL INDUSTRIES LTD.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
43. FRESENIUS SE & CO. KGAA
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
44. GLAXOSMITHKLINE PLC
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
45. PFIZER INC.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
46. ARROTEX AUSTRALIA GROUP
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
47. GRUNENTHAL
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
48. NOVARTIS AG
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
49. ANALYST OPINION
50. ANNEXURE
51. REPORT SCOPE
52. MARKET DEFINITIONS
53. RESEARCH METHODOLOGY
a. Data Collation and In-house Estimation
b. Market Triangulation
c. Forecasting
54. REPORT ASSUMPTIONS
55. DECLARATIONS
56. STAKEHOLDERS
57. ABBREVIATIONS
2. INDUSTRY OUTLOOK
3. INDUSTRY OVERVIEW
4. INDUSTRY TRENDS
5. MARKET SNAPSHOT
6. MARKET DEFINITION
7. MARKET OUTLOOK
a. Porter Five Forces
8. RELATED MARKETS
9. MARKET CHARACTERISTICS
10. MARKET OVERVIEW
11. MARKET SEGMENTATION
12. MARKET DYNAMICS
a. Drivers
b. Restraints
c. Opportunities
13. DRO - IMPACT ANALYSIS
14. DRUG CLASS: MARKET SIZE & ANALYSIS
15. OVERVIEW
16. ERGOT DERIVATIVES
17. CALCIUM CHANNEL BLOCKERS
18. TRIPTANS
19. OTHERS
20. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
21. OVERVIEW
22. HOSPITAL PHARMACIES
23. DRUG STORES AND RETAIL PHARMACIES
24. OTHERS
25. TYPE: MARKET SIZE & ANALYSIS
26. OVERVIEW
27. EPISODIC
28. CHRONIC
29. GEOGRAPHY: MARKET SIZE & ANALYSIS
30. OVERVIEW
31. NORTH AMERICA
32. EUROPE
33. ASIA PACIFIC
34. REST OF THE WORLD
35. COMPETITIVE LANDSCAPE
36. COMPETITOR COMPARISON ANALYSIS
37. MARKET DEVELOPMENTS
a. Mergers and Acquisitions, Legal, Awards, Partnerships
b. Product Launches and execution
38. VENDOR PROFILES
39. DR. REDDY’S LABORATORIES LTD.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
40. ELI LILLY AND COMPANY
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
41. SUN PHARMACEUTICAL INDUSTRIES LTD.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
42. TEVA PHARMACEUTICAL INDUSTRIES LTD.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
43. FRESENIUS SE & CO. KGAA
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
44. GLAXOSMITHKLINE PLC
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
45. PFIZER INC.
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
46. ARROTEX AUSTRALIA GROUP
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
47. GRUNENTHAL
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
48. NOVARTIS AG
a. Overview
b. Financial Overview
c. Product Offerings
d. Developments
e. Business Strategy
49. ANALYST OPINION
50. ANNEXURE
51. REPORT SCOPE
52. MARKET DEFINITIONS
53. RESEARCH METHODOLOGY
a. Data Collation and In-house Estimation
b. Market Triangulation
c. Forecasting
54. REPORT ASSUMPTIONS
55. DECLARATIONS
56. STAKEHOLDERS
57. ABBREVIATIONS
LIST OF TABLES
TABLE 1. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR ERGOT DERIVATIVES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR TRIPTANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR EPISODIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR CHRONIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. U.S CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 17. U.S CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. U.S CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. CANADA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 20. CANADA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. CANADA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. EUROPE CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 24. EUROPE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. EUROPE CLUSTER HEADACHE MARKET VALUE, TYPE, 2021-2027 (USD BILLION)
TABLE 26. GERMANY CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 27. GERMANY CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. GERMANY CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.K CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 30. U.K CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. U.K CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. FRANCE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 33. FRANCE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. FRANCE CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. ITALY CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 36. ITALY CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. ITALY CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. SPAIN CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 39. SPAIN CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. SPAIN CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. ROE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 42. ROE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ROE CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. CHINA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 49. CHINA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. CHINA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. INDIA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 52. INDIA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. INDIA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. JAPAN CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 55. JAPAN CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. JAPAN CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 63. DR. REDDY’S LABORATORIES LTD.: FINANCIALS
TABLE 64. DR. REDDY’S LABORATORIES LTD.: PRODUCTS & TYPES
TABLE 65. DR. REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 66. ELI LILLY AND COMPANY: FINANCIALS
TABLE 67. ELI LILLY AND COMPANY: PRODUCTS & TYPES
TABLE 68. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & TYPES
TABLE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 73. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & TYPES
TABLE 74. TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 75. FRESENIUS SE & CO. KGAA: FINANCIALS
TABLE 76. FRESENIUS SE & CO. KGAA: PRODUCTS & TYPES
TABLE 77. FRESENIUS SE & CO. KGAA: RECENT DEVELOPMENTS
TABLE 78. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 79. GLAXOSMITHKLINE PLC: PRODUCTS & TYPES
TABLE 80. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 81. PFIZER INC.: FINANCIALS
TABLE 82. PFIZER INC.: PRODUCTS & TYPES
TABLE 83. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 84. ARROTEX AUSTRALIA GROUP: FINANCIALS
TABLE 85. ARROTEX AUSTRALIA GROUP: PRODUCTS & TYPES
TABLE 86. ARROTEX AUSTRALIA GROUP: RECENT DEVELOPMENTS
TABLE 87. GRUNENTHAL: FINANCIALS
TABLE 88. GRUNENTHAL: PRODUCTS & TYPES
TABLE 89. GRUNENTHAL: RECENT DEVELOPMENTS
TABLE 90. NOVARTIS AG: FINANCIALS
TABLE 91. NOVARTIS AG: PRODUCTS & TYPES
TABLE 92. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 1. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR ERGOT DERIVATIVES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR TRIPTANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR EPISODIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL CLUSTER HEADACHE MARKET VALUE FOR CHRONIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. U.S CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 17. U.S CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. U.S CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. CANADA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 20. CANADA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. CANADA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. EUROPE CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 24. EUROPE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. EUROPE CLUSTER HEADACHE MARKET VALUE, TYPE, 2021-2027 (USD BILLION)
TABLE 26. GERMANY CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 27. GERMANY CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. GERMANY CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.K CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 30. U.K CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. U.K CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. FRANCE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 33. FRANCE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. FRANCE CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. ITALY CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 36. ITALY CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. ITALY CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. SPAIN CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 39. SPAIN CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. SPAIN CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. ROE CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 42. ROE CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ROE CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. CHINA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 49. CHINA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. CHINA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. INDIA CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 52. INDIA CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. INDIA CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. JAPAN CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 55. JAPAN CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. JAPAN CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY DRUG CLASS, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD CLUSTER HEADACHE MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 63. DR. REDDY’S LABORATORIES LTD.: FINANCIALS
TABLE 64. DR. REDDY’S LABORATORIES LTD.: PRODUCTS & TYPES
TABLE 65. DR. REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 66. ELI LILLY AND COMPANY: FINANCIALS
TABLE 67. ELI LILLY AND COMPANY: PRODUCTS & TYPES
TABLE 68. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & TYPES
TABLE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 73. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & TYPES
TABLE 74. TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 75. FRESENIUS SE & CO. KGAA: FINANCIALS
TABLE 76. FRESENIUS SE & CO. KGAA: PRODUCTS & TYPES
TABLE 77. FRESENIUS SE & CO. KGAA: RECENT DEVELOPMENTS
TABLE 78. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 79. GLAXOSMITHKLINE PLC: PRODUCTS & TYPES
TABLE 80. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 81. PFIZER INC.: FINANCIALS
TABLE 82. PFIZER INC.: PRODUCTS & TYPES
TABLE 83. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 84. ARROTEX AUSTRALIA GROUP: FINANCIALS
TABLE 85. ARROTEX AUSTRALIA GROUP: PRODUCTS & TYPES
TABLE 86. ARROTEX AUSTRALIA GROUP: RECENT DEVELOPMENTS
TABLE 87. GRUNENTHAL: FINANCIALS
TABLE 88. GRUNENTHAL: PRODUCTS & TYPES
TABLE 89. GRUNENTHAL: RECENT DEVELOPMENTS
TABLE 90. NOVARTIS AG: FINANCIALS
TABLE 91. NOVARTIS AG: PRODUCTS & TYPES
TABLE 92. NOVARTIS AG: RECENT DEVELOPMENTS
